Company news: Human Genome Sciences

Share this article:
Human Genome Sciences is laying off 150, mostly in manufacturing, due to slow demand for Benlysta, reports The Washington Post, which said CEO H. Thomas Watkins told investors last week that the company was "pleased" with sales for the first few quarters, which have built gradually, but that Wall Street has failed to understand the drug's trajectory and to price the company's stock accordingly.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.